<DOC>
	<DOC>NCT00359671</DOC>
	<brief_summary>A study to evaluate safety and tolerability of MK6592 in combination with an anti-cancer drug in adult patients with advanced solid tumors.</brief_summary>
	<brief_title>Treatment With MK6592 and an Anti-cancer Drug in Patients With Advanced Solid Tumors (6592-001)</brief_title>
	<detailed_description />
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Patients with advanced solid tumors (metastatic or local) unresponsive to standard therapy, progressed on standard therapy, or no standard therapy exists. No limit to the number of prior treatment regimens Patients may be fully active without physical restrictions, ambulatory with restrictions on strenuous physical activity, or ambulatory and capable of selfcare but not work activities (i.e., Eastern Cooperative Oncology Group performance status of greater than or equal to 2) Demonstrates adequate organ function (liver, kidneys, hematologic) Chemotherapy or radiation therapy within 2 weeks of dosing; or unresolved side effects(s) from prior treatment regimen Participation in an investigational study within 14 days of dosing Primary central nervous system tumor Active brain or spinal cord metastases. Patients who completed a course of therapy for CNS metastases may be eligible if considered clinically stable for 3 months prior to study entry Symptoms from fluid in the abdomen or around the lungs Requires certain drugs or other products known to be metabolized by the liver enzyme CYP3A4</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>